Request Sample Inquiry
Multiple Sclerosis Drugs Market

Multiple Sclerosis Drugs Market

Multiple Sclerosis Drugs Market - Global Industry Assessment & Forecast

img
Healthcare
Number Of Pages # Pages:

147

Base Year:

2022

Date

Oct - 2022

Format:

PDF XLS PPT

Report Code:

VMR-1859

Segments Covered
  • By Drug Class By Drug Class Immunosuppressants, Immunomodulators, Interferons, Other Drug Classes
  • By Route of Administration By Route of Administration Oral, Injectable
  • By Distribution Channel By Distribution Channel Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
  • By Region By Region North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Snapshot
Base YearBase Year: 2022
Forecast YearsForecast Years: 2023 - 2030
Historical YearsHistorical Years: 2017 - 2021
Revenue 2022Revenue 2022: USD 25.90 Billion
Revenue 2030Revenue 2030: USD 34.36 Billion
Revenue CAGRRevenue CAGR (2023 - 2030): 3.60%
Fastest Growing Region Fastest Growing Region (2023 - 2030) Asia Pacific
Largest Region Largest Region (2022): North America
Customization Offered
  • Cross-segment Market Size and Analysis for Mentioned Segments Cross-segment Market Size and Analysis for Mentioned Segments
  • Additional Company Profiles (Upto 5 With No Cost) Additional Company Profiles (Upto 5 With No Cost)
  • Additional Countries (Apart From Mentioned Countries) Additional Countries (Apart From Mentioned Countries)
  • Country/Region-specific Report Country/Region-specific Report
  • Go To Market Strategy Go To Market Strategy
  • Region Specific Market Dynamics Region Specific Market Dynamics
  • Region Level Market Share Region Level Market Share
  • Import Export Analysis Import Export Analysis
  • Production Analysis Production Analysis
  • Other Others Request Customization Speak To Analyst
  1. Executive Dashboard
    1. Strategic Imperatives
  2. Premium Insights
    1. Top 3 Trends to Watch
    2. Demand and Supply Trends
    3. Top 3 Strategies Followed by Major Players
    4. Top 3 Predictions by Vantage Market Research
    5. Top Investment Pockets
    6. Insights from Primary Respondents
  3. Global Multiple Sclerosis Drugs Market - Segment Analysis
    1. Overview
    2. Global Multiple Sclerosis Drugs Market, 2016 - 2028 (USD Million)
    3. Global Multiple Sclerosis Drugs Market - by Drug Class
      1. By Immunosuppressants
      2. By Immunomodulators
      3. By Interferons
      4. By Other Drug Classes
    4. Global Multiple Sclerosis Drugs Market - by Route of Administration
      1. By Oral
      2. By Injectable
    5. Global Multiple Sclerosis Drugs Market - by Distribution Channel
      1. By Hospital Pharmacy
      2. By Retail Pharmacy
      3. By Online Pharmacy
    6. Global Multiple Sclerosis Drugs Market - by region
      1. North America
      2. Europe
      3. Asia Pacific
      4. Latin America
      5. Middle East & Africa
    7. Market comparative analysis
  4. North America Multiple Sclerosis Drugs Market - Segment Analysis
    1. Overview
    2. North America Multiple Sclerosis Drugs Market, 2016 - 2028 (USD Million)
    3. North America Multiple Sclerosis Drugs Market, by Drug Class
      1. By Immunosuppressants
      2. By Immunomodulators
      3. By Interferons
      4. By Other Drug Classes
    4. North America Multiple Sclerosis Drugs Market, by Route of Administration
      1. By Oral
      2. By Injectable
    5. North America Multiple Sclerosis Drugs Market, by Distribution Channel
      1. By Hospital Pharmacy
      2. By Retail Pharmacy
      3. By Online Pharmacy
    6. North America Multiple Sclerosis Drugs Market, by Country
      1. U.S.
        1. U.S. Multiple Sclerosis Drugs Market, By Drug Class
          1. By Immunosuppressants
          2. By Immunomodulators
          3. By Interferons
          4. By Other Drug Classes
        2. U.S. Multiple Sclerosis Drugs Market, By Route of Administration
          1. By Oral
          2. By Injectable
        3. U.S. Multiple Sclerosis Drugs Market, By Distribution Channel
          1. By Hospital Pharmacy
          2. By Retail Pharmacy
          3. By Online Pharmacy
      2. Canada
        1. Canada Multiple Sclerosis Drugs Market, By Drug Class
          1. By Immunosuppressants
          2. By Immunomodulators
          3. By Interferons
          4. By Other Drug Classes
        2. Canada Multiple Sclerosis Drugs Market, By Route of Administration
          1. By Oral
          2. By Injectable
        3. Canada Multiple Sclerosis Drugs Market, By Distribution Channel
          1. By Hospital Pharmacy
          2. By Retail Pharmacy
          3. By Online Pharmacy
      3. Mexico
        1. Mexico Multiple Sclerosis Drugs Market, By Drug Class
          1. By Immunosuppressants
          2. By Immunomodulators
          3. By Interferons
          4. By Other Drug Classes
        2. Mexico Multiple Sclerosis Drugs Market, By Route of Administration
          1. By Oral
          2. By Injectable
        3. Mexico Multiple Sclerosis Drugs Market, By Distribution Channel
          1. By Hospital Pharmacy
          2. By Retail Pharmacy
          3. By Online Pharmacy
  5. Europe Multiple Sclerosis Drugs Market - Segment Analysis
    1. Overview
    2. Europe Multiple Sclerosis Drugs Market, 2016 - 2028 (USD Million)
    3. Europe Multiple Sclerosis Drugs Market, by Drug Class
      1. By Immunosuppressants
      2. By Immunomodulators
      3. By Interferons
      4. By Other Drug Classes
    4. Europe Multiple Sclerosis Drugs Market, by Route of Administration
      1. By Oral
      2. By Injectable
    5. Europe Multiple Sclerosis Drugs Market, by Distribution Channel
      1. By Hospital Pharmacy
      2. By Retail Pharmacy
      3. By Online Pharmacy
    6. Europe Multiple Sclerosis Drugs Market, by Country
      1. Germany
        1. Germany Multiple Sclerosis Drugs Market, By Drug Class
          1. By Immunosuppressants
          2. By Immunomodulators
          3. By Interferons
          4. By Other Drug Classes
        2. Germany Multiple Sclerosis Drugs Market, By Route of Administration
          1. By Oral
          2. By Injectable
        3. Germany Multiple Sclerosis Drugs Market, By Distribution Channel
          1. By Hospital Pharmacy
          2. By Retail Pharmacy
          3. By Online Pharmacy
      2. UK
        1. UK Market, By Drug Class
          1. By Immunosuppressants
          2. By Immunomodulators
          3. By Interferons
          4. By Other Drug Classes
        2. UK Market, By Route of Administration
          1. By Oral
          2. By Injectable
        3. UK Market, By Distribution Channel
          1. By Hospital Pharmacy
          2. By Retail Pharmacy
          3. By Online Pharmacy
      3. France
        1. France Multiple Sclerosis Drugs Market, By Drug Class
          1. By Immunosuppressants
          2. By Immunomodulators
          3. By Interferons
          4. By Other Drug Classes
        2. France Multiple Sclerosis Drugs Market, By Route of Administration
          1. By Oral
          2. By Injectable
        3. France Multiple Sclerosis Drugs Market, By Distribution Channel
          1. By Hospital Pharmacy
          2. By Retail Pharmacy
          3. By Online Pharmacy
      4. Spain
        1. Spain Multiple Sclerosis Drugs Market, By Drug Class
          1. By Immunosuppressants
          2. By Immunomodulators
          3. By Interferons
          4. By Other Drug Classes
        2. Spain Multiple Sclerosis Drugs Market, By Route of Administration
          1. By Oral
          2. By Injectable
        3. Spain Multiple Sclerosis Drugs Market, By Distribution Channel
          1. By Hospital Pharmacy
          2. By Retail Pharmacy
          3. By Online Pharmacy
      5. Italy
        1. Italy Multiple Sclerosis Drugs Market, By Drug Class
          1. By Immunosuppressants
          2. By Immunomodulators
          3. By Interferons
          4. By Other Drug Classes
        2. Italy Multiple Sclerosis Drugs Market, By Route of Administration
          1. By Oral
          2. By Injectable
        3. Italy Multiple Sclerosis Drugs Market, By Distribution Channel
          1. By Hospital Pharmacy
          2. By Retail Pharmacy
          3. By Online Pharmacy
      6. BENELUX
        1. BENELUX Multiple Sclerosis Drugs Market, By Drug Class
          1. By Immunosuppressants
          2. By Immunomodulators
          3. By Interferons
          4. By Other Drug Classes
        2. BENELUX Multiple Sclerosis Drugs Market, By Route of Administration
          1. By Oral
          2. By Injectable
        3. BENELUX Multiple Sclerosis Drugs Market, By Distribution Channel
          1. By Hospital Pharmacy
          2. By Retail Pharmacy
          3. By Online Pharmacy
      7. Rest of Europe
        1. Rest Of Europe Multiple Sclerosis Drugs Market, By Drug Class
          1. By Immunosuppressants
          2. By Immunomodulators
          3. By Interferons
          4. By Other Drug Classes
        2. Rest Of Europe Multiple Sclerosis Drugs Market, By Route of Administration
          1. By Oral
          2. By Injectable
        3. Rest Of Europe Multiple Sclerosis Drugs Market, By Distribution Channel
          1. By Hospital Pharmacy
          2. By Retail Pharmacy
          3. By Online Pharmacy
  6. Asia Pacific Multiple Sclerosis Drugs Market - Segment Analysis
    1. Overview
    2. Asia Pacific Multiple Sclerosis Drugs Market, 2016 - 2028 (USD Million)
    3. Asia Pacific Multiple Sclerosis Drugs Market, by Drug Class
      1. By Immunosuppressants
      2. By Immunomodulators
      3. By Interferons
      4. By Other Drug Classes
    4. Asia Pacific Multiple Sclerosis Drugs Market, by Route of Administration
      1. By Oral
      2. By Injectable
    5. Asia Pacific Multiple Sclerosis Drugs Market, by Distribution Channel
      1. By Hospital Pharmacy
      2. By Retail Pharmacy
      3. By Online Pharmacy
    6. Asia Pacific Multiple Sclerosis Drugs Market, by Country
      1. China
        1. China Multiple Sclerosis Drugs Market, By Drug Class
          1. By Immunosuppressants
          2. By Immunomodulators
          3. By Interferons
          4. By Other Drug Classes
        2. China Multiple Sclerosis Drugs Market, By Route of Administration
          1. By Oral
          2. By Injectable
        3. China Multiple Sclerosis Drugs Market, By Distribution Channel
          1. By Hospital Pharmacy
          2. By Retail Pharmacy
          3. By Online Pharmacy
      2. Japan
        1. Japan Multiple Sclerosis Drugs Market, By Drug Class
          1. By Immunosuppressants
          2. By Immunomodulators
          3. By Interferons
          4. By Other Drug Classes
        2. Japan Multiple Sclerosis Drugs Market, By Route of Administration
          1. By Oral
          2. By Injectable
        3. Japan Multiple Sclerosis Drugs Market, By Distribution Channel
          1. By Hospital Pharmacy
          2. By Retail Pharmacy
          3. By Online Pharmacy
      3. India
        1. India Multiple Sclerosis Drugs Market, By Drug Class
          1. By Immunosuppressants
          2. By Immunomodulators
          3. By Interferons
          4. By Other Drug Classes
        2. India Multiple Sclerosis Drugs Market, By Route of Administration
          1. By Oral
          2. By Injectable
        3. India Multiple Sclerosis Drugs Market, By Distribution Channel
          1. By Hospital Pharmacy
          2. By Retail Pharmacy
          3. By Online Pharmacy
      4. South Korea
        1. South Korea Multiple Sclerosis Drugs Market, By Drug Class
          1. By Immunosuppressants
          2. By Immunomodulators
          3. By Interferons
          4. By Other Drug Classes
        2. South Korea Multiple Sclerosis Drugs Market, By Route of Administration
          1. By Oral
          2. By Injectable
        3. South Korea Multiple Sclerosis Drugs Market, By Distribution Channel
          1. By Hospital Pharmacy
          2. By Retail Pharmacy
          3. By Online Pharmacy
      5. South East Asia
        1. South East Asia Multiple Sclerosis Drugs Market, By Drug Class
          1. By Immunosuppressants
          2. By Immunomodulators
          3. By Interferons
          4. By Other Drug Classes
        2. South East Asia Multiple Sclerosis Drugs Market, By Route of Administration
          1. By Oral
          2. By Injectable
        3. South East Asia Multiple Sclerosis Drugs Market, By Distribution Channel
          1. By Hospital Pharmacy
          2. By Retail Pharmacy
          3. By Online Pharmacy
      6. Rest of Asia Pacific
        1. Rest of Asia Pacific Multiple Sclerosis Drugs Market, By Drug Class
          1. By Immunosuppressants
          2. By Immunomodulators
          3. By Interferons
          4. By Other Drug Classes
        2. Rest of Asia Pacific Multiple Sclerosis Drugs Market, By Route of Administration
          1. By Oral
          2. By Injectable
        3. Rest of Asia Pacific Multiple Sclerosis Drugs Market, By Distribution Channel
          1. By Hospital Pharmacy
          2. By Retail Pharmacy
          3. By Online Pharmacy
  7. Latin America Multiple Sclerosis Drugs Market - Segment Analysis
    1. Overview
    2. Latin America Multiple Sclerosis Drugs Market, 2016 - 2028 (USD Million)
    3. Latin America Multiple Sclerosis Drugs Market, by Drug Class
      1. By Immunosuppressants
      2. By Immunomodulators
      3. By Interferons
      4. By Other Drug Classes
    4. Latin America Multiple Sclerosis Drugs Market, by Route of Administration
      1. By Oral
      2. By Injectable
    5. Latin America Multiple Sclerosis Drugs Market, by Distribution Channel
      1. By Hospital Pharmacy
      2. By Retail Pharmacy
      3. By Online Pharmacy
    6. Latin America Multiple Sclerosis Drugs Market, by Country
      1. Brazil
        1. Brazil Multiple Sclerosis Drugs Market, By Drug Class
          1. By Immunosuppressants
          2. By Immunomodulators
          3. By Interferons
          4. By Other Drug Classes
        2. Brazil Multiple Sclerosis Drugs Market, By Route of Administration
          1. By Oral
          2. By Injectable
        3. Brazil Multiple Sclerosis Drugs Market, By Distribution Channel
          1. By Hospital Pharmacy
          2. By Retail Pharmacy
          3. By Online Pharmacy
      2. Argentina
        1. Argentina Multiple Sclerosis Drugs Market, By Drug Class
          1. By Immunosuppressants
          2. By Immunomodulators
          3. By Interferons
          4. By Other Drug Classes
        2. Argentina Multiple Sclerosis Drugs Market, By Route of Administration
          1. By Oral
          2. By Injectable
        3. Argentina Multiple Sclerosis Drugs Market, By Distribution Channel
          1. By Hospital Pharmacy
          2. By Retail Pharmacy
          3. By Online Pharmacy
      3. Rest of Latin America
        1. Rest of Latin America Multiple Sclerosis Drugs Market, By Drug Class
          1. By Immunosuppressants
          2. By Immunomodulators
          3. By Interferons
          4. By Other Drug Classes
        2. Rest of Latin America Multiple Sclerosis Drugs Market, By Route of Administration
          1. By Oral
          2. By Injectable
        3. Rest of Latin America Multiple Sclerosis Drugs Market, By Distribution Channel
          1. By Hospital Pharmacy
          2. By Retail Pharmacy
          3. By Online Pharmacy
  8. Middle East & Africa Multiple Sclerosis Drugs Market - Segment Analysis
    1. Overview
    2. Middle East & Africa Multiple Sclerosis Drugs Market, 2016 - 2028 (USD Million)
    3. Middle East & Africa Multiple Sclerosis Drugs Market, by Drug Class
      1. By Immunosuppressants
      2. By Immunomodulators
      3. By Interferons
      4. By Other Drug Classes
    4. Middle East & Africa Multiple Sclerosis Drugs Market, by Route of Administration
      1. By Oral
      2. By Injectable
    5. Middle East & Africa Multiple Sclerosis Drugs Market, by Distribution Channel
      1. By Hospital Pharmacy
      2. By Retail Pharmacy
      3. By Online Pharmacy
    6. Middle East & Africa Multiple Sclerosis Drugs Market, by Country
      1. GCC Countries
        1. GCC Countries Multiple Sclerosis Drugs Market, By Drug Class
          1. By Immunosuppressants
          2. By Immunomodulators
          3. By Interferons
          4. By Other Drug Classes
        2. GCC Countries Multiple Sclerosis Drugs Market, By Route of Administration
          1. By Oral
          2. By Injectable
        3. GCC Countries Multiple Sclerosis Drugs Market, By Distribution Channel
          1. By Hospital Pharmacy
          2. By Retail Pharmacy
          3. By Online Pharmacy
      2. South Africa
        1. South Africa Multiple Sclerosis Drugs Market, By Drug Class
          1. By Immunosuppressants
          2. By Immunomodulators
          3. By Interferons
          4. By Other Drug Classes
        2. South Africa Multiple Sclerosis Drugs Market, By Route of Administration
          1. By Oral
          2. By Injectable
        3. South Africa Multiple Sclerosis Drugs Market, By Distribution Channel
          1. By Hospital Pharmacy
          2. By Retail Pharmacy
          3. By Online Pharmacy
      3. Rest of Middle East & Africa
        1. Rest of Middle East & Africa Multiple Sclerosis Drugs Market, By Drug Class
          1. By Immunosuppressants
          2. By Immunomodulators
          3. By Interferons
          4. By Other Drug Classes
        2. Rest of Middle East & Africa Multiple Sclerosis Drugs Market, By Route of Administration
          1. By Oral
          2. By Injectable
        3. Rest of Middle East & Africa Multiple Sclerosis Drugs Market, By Distribution Channel
          1. By Hospital Pharmacy
          2. By Retail Pharmacy
          3. By Online Pharmacy
  9. Key Market Dynamics
    1. Introduction
    2. Market Drivers
    3. Market Restraints
    4. Market Opportunities
    5. Porter's Five Forces Analysis
    6. PEST Analysis
    7. Regulatory Landscape
    8. Technology Landscape
    9. Regional Market Trends
  10. COVID 19 Impact Analysis
    1. Key strategies undertaken by companies to tackle COVID-19
    2. Short term dynamics
    3. Long term dynamics
  11. Marketing Stratagy Analysis
    1. Marketing Channel
    2. Direct Marketing
    3. Indirect Marketing
    4. Marketing Channel Development Trends
  12. Competative Landscape
    1. Competition Matrix - 2021
    2. Company Market Share Analysis - 2021
    3. Key Company Activities, 2018 - 2021
    4. Strategic Developments - Heat Map Analysis
    5. Company Offering Evaluation
    6. Company Regional Presence Evaluation
  13. Company Profiles
    1. Celgene Corporation
    2. Acorda Therapeutics Inc.
    3. Biogen Inc.
    4. Actelion Pharmaceuticals (Johnson & Johnson)
    5. EMD Serono (Merck KGaA)
    6. Bayer AG
    7. Teva Pharmaceutical Industries Ltd.
    8. Novartis AG.
    9. Sanofi
    10. F. Hoffmann-La Roche Ltd.
  14. Key Primary Respondents - VERBATIM
  15. Discussion Guide
  16. Customization Offered
  17. Annexure
  18. List of Figures
  19. List of Tables
  20. List of Abbreviations
Vantage Market Research | 10-Oct-2022
Multiple Sclerosis Drugs Market to Reach Valuation of USD 31.2 Billion by 2028 – Growth in Incidence of Multiple Sclerosis and Rising Investments for Healthcare Infrastructure Drives the Market
FAQ
Frequently Asked Question

  • The global Multiple Sclerosis Drugs valued at USD 25.90 Billion in 2022 and is expected to reach USD 34.36 Billion in 2030 growing at a CAGR of 3.60%.

  • The prominent players in the market are Celgene Corporation, Acorda Therapeutics Inc., Biogen Inc., Actelion Pharmaceuticals (Johnson & Johnson), EMD Serono (Merck KGaA), Bayer AG, Teva Pharmaceutical Industries Ltd., Novartis AG., Sanofi, F. Hoffmann-La Roche Ltd..

  • The market is project to grow at a CAGR of 3.60% between 2023 and 2030.

  • The driving factors of the Multiple Sclerosis Drugs include

    • Significant R&D Investment by Market Players to Boost the Market

  • North America was the leading regional segment of the Multiple Sclerosis Drugs in 2022.

Related Reports
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies Privacy Policy